Xiaoyang Liu

Dr. Xiaoyang Liu


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2023 in Radiology: Imaging Cancer
Verified
Journal Article
Closed access
ESEva Mendes Serrão
Eva Mendes Serrão
MKMaximiliano Klug
Maximiliano Klug
BMBrian M. Moloney
Brian M. Moloney
AJAaditeya Jhaveri
Aaditeya Jhaveri
RGRoberto Lo Gullo
Roberto Lo Gullo
XLXiaoyang Liu
Xiaoyang Liu
Ongoing discoveries in cancer genomics and epigenomics have revolutionized clinical oncology and precision health care. This knowledge provides unprecedented insights into tumor biology and heterogeneity within a single tumor, among primary and metastatic lesions, and among patients with the same histologic type of cancer. Large-scale genomic sequencing studies also sparked the development of new tumor classifications, biomarkers, and targeted therapies. Because of the central role of imaging in cancer diagnosis and therapy, radiologists need to be familiar with the basic concepts of genomics, which are now becoming the new norm in oncologic clinical practice. By incorporating these concepts into clinical practice, radiologists can make their imaging interpretations more meaningful and specific, facilitate multidisciplinary clinical dialogue and interventions, and provide better patient-centric care. This review article highlights basic concepts of genomics and epigenomics, reviews the most common genetic alterations in cancer, and discusses the implications of these concepts on imaging by organ system in a case-based manner. This information will help stimulate new innovations in imaging research, accelerate the development and validation of new imaging biomarkers, and motivate efforts to bring new molecular and functional imaging methods to clinical radiology. Keywords: Oncology, Cancer Genomics, Epignomics, Radiogenomics, Imaging Markers Supplemental material is available for this article. © RSNA, 2023.

1 September 2023 in RadioGraphics
Verified
Journal Article
Closed access
XLXiaoyang Liu
Xiaoyang Liu
STStephanie B. M. Tan
Stephanie B. M. Tan
MAMuhammad O. Awiwi
Muhammad O. Awiwi
HJHyun-Jung Jang
Hyun-Jung Jang
VCVictoria Chernyak
Victoria Chernyak
KEKhaled M. Elsayes
Khaled M. Elsayes
Cirrhosis is the end stage of chronic liver disease and causes architectural distortion and perfusional anomalies. It is a major risk factor for developing hepatocellular carcinoma (HCC). Common disease entities in noncirrhotic livers, such as hemangiomas, can be rare in cirrhotic livers, and benign entities such as confluent hepatic fibrosis and focal nodular hyperplasia-like lesions may mimic the appearance of malignancies,. HCC usually has typical imaging characteristics, such as the major features established by the Liver Imaging Reporting and Data System. However, HCC can also have a spectrum of atypical or uncommon appearances, such as cystic HCC, hypovascular HCC, or macroscopic fat-containing HCC. HCCs with certain genetic mutations such as CTNNB-1-mutated HCC can harbor unique imaging features not seen in other types of HCC. In addition, malignancies that are less common than HCC, such as cholangiocarcinoma and metastases, which can be difficult to differentiate, can still occur in cirrhotic livers. Atypical imaging features of benign and malignant lesions can be challenging to accurately diagnose. Therefore, familiarity with these features and an understanding of the prevalence of disease entities in cirrhotic livers are key in the daily practice of radiologists for evaluation of cirrhotic livers. The authors illustrate the typical and atypical features of benign and malignant lesions in cirrhosis and discuss the technical pitfalls and unique advantages associated with various imaging modalities in assessing cirrhotic livers, including noncontrast and contrast-enhanced US, CT, and MRI. Work of the U.S. Government published under an exclusive license with the RSNA. Quiz questions for this article are available in the supplemental material.

24 July 2021 in Cancers
Verified
Journal Article
Open access
PDF file
XLXiaoyang Liu
Xiaoyang Liu
FMFarhad Maleki
Farhad Maleki
NMNikesh Muthukrishnan
Nikesh Muthukrishnan
KOKatie Ovens
Katie Ovens
SHShao Hui Huang
Shao Hui Huang
RFReza Forghani
Reza Forghani
Current radiomic studies of head and neck squamous cell carcinomas (HNSCC) are typically based on datasets combining tumors from different locations, assuming that the radiomic features are similar based on histopathologic characteristics. However, molecular pathogenesis and treatment in HNSCC substantially vary across different tumor sites. It is not known if a statistical difference exists between radiomic features from different tumor sites and how they affect machine learning model performance in endpoint prediction. To answer these questions, we extracted radiomic features from contrast-enhanced neck computed tomography scans (CTs) of 605 patients with HNSCC originating from the oral cavity, oropharynx, and hypopharynx/larynx. The difference in radiomic features of tumors from these sites was assessed using statistical analyses and Random Forest classifiers on the radiomic features with 10-fold cross-validation to predict tumor sites, nodal metastasis, and HPV status. We found statistically significant differences (p-value ≤ 0.05) between the radiomic features of HNSCC depending on tumor location. We also observed that differences in quantitative features among HNSCC from different locations impact the performance of machine learning models. This suggests that radiomic features may reveal biologic heterogeneity complementary to current gold standard histopathologic evaluation. We recommend considering tumor site in radiomic studies of HNSCC.

18 March 2023 in Abdominal Radiology
Verified
Journal Article
Closed access
PDF file
XLXiaoyang Liu
Xiaoyang Liu
YGYang Guo
Yang Guo
LZLei Zhao
Lei Zhao
JMJoseph Misdraji
Joseph Misdraji
TKTina Kapur
Tina Kapur
PSPaul B. Shyn
Paul B. Shyn

11 November 2024 in Abdominal Radiology
Verified
Journal Article
Open access
PDF file
JHJason Heald
Jason Heald
DFDavid T. Fetzer
David T. Fetzer
SRShuchi Rodgers
Shuchi Rodgers
VJVaibhav Jain
Vaibhav Jain
AFAlice Fung
Alice Fung
RMRobert M. Marks
Robert M. Marks
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide and is the fastest growing cause of cancer death in the United States (U.S.) In the U.S., current national clinical practice guidelines from the 2023 American Association for the Study of Liver Diseases (AASLD) Practice Guidance and the recently updated Liver Imaging Reporting & Data Systems (LI-RADS) Ultrasound (US) Surveillance v2024 core recommend semi-annual serum α-fetoprotein and US screening of patients deemed to be high risk for developing HCC. In this article, we will explore the transition to a patient-centered approach to HCC surveillance, including the role of the new LI-RADS US Surveillance v2024 core and the use of visualization score for determining ultrasound quality, the known risk factors for poor US image quality, and the potential options for alternative surveillance strategies when US may not be a viable option for certain patients, including multiphasic computed tomography (CT), magnetic resonance imaging (MRI), and several abbreviated MRI protocols.

23 October 2024 in Abdominal Radiology
Verified
Journal Article
Open access
PDF file
MIMohammed Ismail
Mohammed Ismail
TLTasneem Lalani
Tasneem Lalani
AKAnia Kielar
Ania Kielar
CHCheng Hong
Cheng Hong
JYJoseph Yacoub
Joseph Yacoub
JLJames Lee
James Lee
The establishment of the Liver Imaging Reporting and Data System (LI-RADS) in 2011 provided a comprehensive approach to standardized imaging, interpretation, and reporting of liver observations in patients diagnosed with or at risk for hepatocellular carcinoma (HCC). Each set of algorithms provides criteria pertinent to the various components of HCC management including surveillance, diagnosis, staging, and treatment response supported by a detailed lexicon of terms applicable to a wide range of liver imaging scenarios. Before its widespread adoption, the variability in the terminology of diagnostic criteria and definitions of imaging features led to significant challenges in patient management and made it difficult to replicate findings or apply them consistently. The integration of LI-RADS into the clinical setting has enhanced the efficiency and clarity of communication between radiologists, referring providers, and patients by employing a uniform language that averts miscommunications. LI-RADS has been strengthened with its integration into the American Association for Study of Liver Diseases practice guidelines. We will provide the background on the initial development of LI-RADS and reasons for development to serve as a starting point for conveying the system’s benefits and evolution over the years. We will also suggest strategies for the implementation and maintenance of a LI-RADS program will be discussed.